Chimeric receptors and methods of use thereof

A chimeric protein comprising an antigen-binding domain specific for V-Set And Immunoglobulin Domain Containing 2 (VSIG2) and a heterologous molecule or moiety,

• wherein the antigen-binding domain comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein
• (a) the VH comprises:
• a heavy chain complementarity determining region 1 (CDR-H1) having the amino acid sequence of GFTFSNS (SEQ ID NO:2),
• a heavy chain complementarity determining region 2 (CDR-H2) having the amino acid sequence of SDGGLY (SEQ ID NO:3), and
• a heavy chain complementarity determining region 3 (CDR-H3) having the amino acid sequence of QGVRPFFDY (SEQ ID NO:4), and
• the VL comprises:
• a light chain complementarity determining region 1 (CDR-L1) having the amino acid sequence of RASENIYSYLA (SEQ ID NO:
• 11) or RASENLYSYLA (SEQ ID NO:12),
• a light chain complementarity determining region 2 (CDR-L2) having the amino acid sequence of NAETLPE (SEQ ID NO:13), and
• a light chain complementarity determining region 3 (CDR-L3) having the amino acid sequence of QHHYVIPWT (SEQ ID NO:14);
• or
• (b) the VH comprises:
• a heavy chain complementarity determining region 1 (CDR-H1) contained within the VH region amino acid sequence of SEQ ID NO:
• 1, a heavy chain complementarity determining region 2 (CDR-H2) contained within the VH region amino acid sequence of SEQ ID NO:
• 1, and a heavy chain complementarity determining region 3 (CDR-H3) contained within the VH region amino acid sequence of SEQ ID NO:
• 1, and
• the VL comprises:
• a light chain complementarity determining region 1 (CDR-L1) are contained within the VL region amino acid sequence of SEQ ID NO:
• 9, a light chain complementarity determining region 2 (CDR-L2) are contained within the VL region amino acid sequence of SEQ ID NO:
• 9, and a light chain complementarity determining region 3 (CDR-L3) are contained within the VL region amino acid sequence of SEQ ID NO:
• 9;
• or
• (c) the VH comprises:
• a heavy chain complementarity determining region 1 (CDR-H1) contained within the VH region amino acid sequence of SEQ ID NO:
• 1, a heavy chain complementarity determining region 2 (CDR-H2) contained within the VH region amino acid sequence of SEQ ID NO:
• 1, and a heavy chain complementarity determining region 3 (CDR-H3) contained within the VH region amino acid sequence of SEQ ID NO:
• 1, and
• the VL comprises:
• a light chain complementarity determining region 1 (CDR-L1) are contained within the VL region amino acid sequence of SEQ ID NO:
• 10, a light chain complementarity determining region 2 (CDR-L2) are contained within the VL region amino acid sequence of SEQ ID NO:10, and a light chain complementarity determining region 3 (CDR-L3) are contained within the VL region amino acid sequence of SEQ ID NO:
• 10, and
• optionally wherein the amino acid sequences of the CDR-H1, the CDR-H2, the CDR-H3, the CDR-L1, the CDR-L2, and the CDR-L3 of the reference antibody are defined based on the Kabat or Chothia numbering scheme.